Browsing: Novo

Novo Nordisk A/S (ISIN DK0062498333) stock is trading in the mid-$40 range for its US-listed ADR as of August 14, 2026, with a closing price of $45.91 and a modest decline of 1.73% on that day, underscoring a period of consolidation after its latest half-year earnings and guidance update. Per recent market data as of…

Readers who want to keep exploring related opportunities in healthcare and drug development can review 44 healthcare AI stocks

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide

Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market’s thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different…

Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly

Novo Nordisk CEO Mike Doustdar on Wednesday defended the drugmaker’s decision to sue rival Eli Lilly over its weight-loss drug advertising

Novo Nordisk (NYSE:NVO) CEO Mike Doustdar is defending the drugmaker’s lawsuit against Eli Lilly (NYSE:LLY), escalating a fight over how the two companies market their blockbuster obesity treatments. The legal battle matters because Lilly has seized the lead in the U.S. obesity-drug market, raising the stakes for Novo as it tries to narrow the efficacy…

NEW YORK, Aug 13 (Reuters) – Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly

Novo Nordisk President and CEO Mike Doustdar discusses the company’s collaboration with artificial intelligence to accelerate drug discovery and development

Giann Liguid is a graduate of Ateneo De Manila University with an AB in Interdisciplinary Studies. With a diverse writing background, Giann has written content for the security, food and business industries. He also has expertise in both the public and private sectors, having worked in the government specializing in local government units and administrative…